Back to search

Article

Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2: A single-center large observational study

2023-10-18

Abstract excerpt

<h4>Objective: </h4> To assess the effectiveness and safety of nirmatrelvir-ritonavir in the treatment of mild-to-moderate COVID-19 caused by the omicron BA. 2. 2 variant. <h4>Methods: </h4>: An observational study was conducted retrospectively to review the outcomes of mild-to-moderate COVID-19 patients admitted between 26 April and 30 June, 2022. Patients’ baseline characteristics were collected and assessed. P...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ff0d76c0-cbb9-5170-82ff-0402e7af8210
DOI
10.22541/au.169760895.58249136/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2: A single-center large observational studyDOI 10.22541/au.169760895.58249136/v1
Real-world Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During the Emergence of Omicron Variants BA.2/BA2.12.1Semantic proximity
Association of Molnupiravir and Nirmatrelvir-Ritonavir with Reduced Mortality and All-cause Sepsis in Hospitalized Patients Infected with Omicron Variant of SARS-CoV-2: A Territory-Wide Prospective Cohort StudySemantic proximity
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)Semantic proximity
Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in EnglandSemantic proximity
Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of ConcernSemantic proximity
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)Semantic proximity
Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong Kong’s Omicron BA.2 wave: an observational studySemantic proximity
Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron SurgeSemantic proximity
Real-Life Comparison of Mortality in Non-Hospitalised Patients with SARS-CoV-2 Infection at Risk for Clinical Progression Treated with Molnupiravir or Nirmatrevir Plus Ritonavir During the Omicron Era in Italy: A Nationwide, Observational StudySemantic proximity
Analysis of Factors Affecting the Nucleic Acid Negative Conversion Time after SARS-CoV-2 Omicron Variant InfectionSemantic proximity
Clinical Symptom Influence on The Time of Nucleic Acid Conversion to Negative in COVID-19 Patients with SARS-CoV-2 Omicron Variant: A Retrospective Observational StudySemantic proximity
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature reviewSemantic proximity
Select a neighboring publication to make it the new centre.